Paul Wheatley-Price
Overview
Explore the profile of Paul Wheatley-Price including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
88
Citations
1715
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chu A, Sehabi W, Kearns E, Aubry T, Nissim R, Wheatley-Price P, et al.
Support Care Cancer
. 2025 Feb;
33(3):152.
PMID: 39907811
Objectives: Individuals with lung cancer are living longer due to recent treatment advances such as immunotherapy and targeted therapy. The preferred label(s) of this new population are unknown. This is...
2.
Immunotherapy for Early-Stage Non-Small Cell Lung Cancer: A Practical Guide of Current Controversies
Phillips W, Jackson A, Kidane B, Lim G, Navani V, Wheatley-Price P
Clin Lung Cancer
. 2025 Feb;
PMID: 39893112
The role of immunotherapy as systemic therapy for nonmetastatic non-small cell lung cancer (NSCLC) has evolved rapidly over the last decade. There are several well-conducted phase 3 clinical trials evaluating...
3.
Phillips W, Camidge D, Wheatley-Price P
J Thorac Oncol
. 2025 Jan;
20(1):30-33.
PMID: 39794103
No abstract available.
4.
Melosky B, Juergens R, Banerji S, Sacher A, Wheatley-Price P, Snow S, et al.
Ther Adv Med Oncol
. 2025 Jan;
17():17588359241308784.
PMID: 39776537
Non-small-cell lung cancer (NSCLC) is a highly heterogeneous disease that is frequently associated with a host of known oncogenic alterations. Advances in molecular diagnostics and drug development have facilitated the...
5.
Wong B, Liu J, Yeo S, Akurang D, Lo A, Xu Y, et al.
Oncologist
. 2024 Nov;
PMID: 39520389
Background: Guidelines for the management of patients with cancer of unknown primary (CUP), who have metastatic disease without an identified primary tumor site, have evolved. We sought to describe the...
6.
Kearns E, Chu A, Nissim R, Wheatley-Price P, Aubry T, Lebel S
Psychooncology
. 2024 Oct;
33(11):e70015.
PMID: 39472304
Objective: Lung cancer is associated with the highest incidence and mortality of all cancers. New treatments, called targeted therapies (TT) and immunotherapies (IO), offer higher treatment efficacy and fewer side...
7.
Quartermain L, Buchan C, Kilabuk E, Wheatley-Price P
Case Rep Oncol
. 2024 Oct;
17(1):1222-1228.
PMID: 39450198
Introduction: Immune-check-point inhibitors (ICIs) are established in the treatment of many malignancies. Many immune-related adverse events (irAEs) are well described; however, there is less information about opportunistic infections in cancer...
8.
Wheatley-Price P, Wong B, Shah H, Sekhon H, Moore S
Front Oncol
. 2024 Oct;
14:1398414.
PMID: 39391245
Introduction: Aberrant expression of anaplastic lymphoma kinase (ALK) is found in 3%-7% of patients with non-small cell lung cancer (NSCLC). Alectinib is a tyrosine kinase inhibitor used as first-line treatment...
9.
Martin J, Alrehaili M, Marginean H, Goodwin R, Wheatley-Price P
Cancer Treat Res Commun
. 2024 Oct;
41:100846.
PMID: 39366307
Introduction: Lung neuroendocrine tumours (LNETs) are a rare heterogenous group of tumours whose incidence has been increasing. We investigated the diagnosis, treatment, and survival patterns of patients with low to...
10.
Piccirillo M, Chu Q, Bradbury P, Tu W, Coschi C, Grosso F, et al.
J Thorac Oncol
. 2024 Aug;
19(11):1578-1579.
PMID: 39186030
No abstract available.